Business Description
This ETF focuses on companies building businesses around psychedelic medicine, putting at least 80% of its money into firms that earn or deploy the majority of their resources in this space. It targets publicly traded life sciences and related companies working to develop psychedelic-based treatments. The fund takes a concentrated approach, meaning it holds fewer positions than a typical diversified fund.
